Amicus Therapeutics (FOLD) Cut to Sell at BidaskClub

BidaskClub downgraded shares of Amicus Therapeutics (NASDAQ:FOLD) from a hold rating to a sell rating in a report published on Thursday morning.

Other analysts have also issued research reports about the company. Chardan Capital boosted their price target on Amicus Therapeutics from $12.50 to $17.50 and gave the company a buy rating in a report on Thursday, August 10th. Robert W. Baird reissued an outperform rating and set a $18.00 price target (up previously from $16.00) on shares of Amicus Therapeutics in a report on Wednesday, October 4th. J P Morgan Chase & Co reaffirmed an overweight rating on shares of Amicus Therapeutics in a research note on Wednesday, October 4th. Cowen reaffirmed a buy rating and issued a $16.00 price objective on shares of Amicus Therapeutics in a research note on Monday, August 14th. Finally, Zacks Investment Research lowered Amicus Therapeutics from a buy rating to a hold rating in a research note on Thursday, October 12th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the company. The company currently has a consensus rating of Buy and an average price target of $17.81.

Amicus Therapeutics (NASDAQ FOLD) opened at $13.27 on Thursday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 6.22 and a current ratio of 6.32. Amicus Therapeutics has a one year low of $4.41 and a one year high of $16.60.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.10). Amicus Therapeutics had a negative net margin of 1,092.37% and a negative return on equity of 63.54%. The firm had revenue of $10.90 million for the quarter, compared to analysts’ expectations of $9.02 million. During the same quarter last year, the company posted ($0.33) EPS. The firm’s revenue was up 419.0% compared to the same quarter last year. equities analysts anticipate that Amicus Therapeutics will post -1.56 EPS for the current fiscal year.

In related news, CEO John F. Crowley sold 47,213 shares of the stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $13.61, for a total value of $642,568.93. Following the transaction, the chief executive officer now owns 375,214 shares of the company’s stock, valued at $5,106,662.54. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Jay Barth sold 5,000 shares of the stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $13.59, for a total value of $67,950.00. Following the completion of the transaction, the insider now directly owns 69,184 shares in the company, valued at approximately $940,210.56. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 680,437 shares of company stock worth $9,734,522. Company insiders own 3.40% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in FOLD. Sage Capital Advisors llc acquired a new stake in shares of Amicus Therapeutics in the 3rd quarter worth $154,000. GSA Capital Partners LLP acquired a new stake in shares of Amicus Therapeutics in the 3rd quarter worth $309,000. Iguana Healthcare Management LLC acquired a new stake in shares of Amicus Therapeutics in the 3rd quarter worth $905,000. Sterling Capital Management LLC acquired a new stake in shares of Amicus Therapeutics in the 3rd quarter worth $218,000. Finally, Neuberger Berman Group LLC acquired a new stake in shares of Amicus Therapeutics in the 3rd quarter worth $196,000.

ILLEGAL ACTIVITY WARNING: “Amicus Therapeutics (FOLD) Cut to Sell at BidaskClub” was originally reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright laws. The original version of this piece can be viewed at https://stocknewstimes.com/2017/12/11/amicus-therapeutics-fold-cut-to-sell-at-bidaskclub.html.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply